- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-30
DOI
10.3389/fonc.2021.700407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
- (2021) Yue Li et al. Frontiers in Pharmacology
- Hypoxia activated prodrug evofosfamide treatment in pancreatic ductal adenocarcinoma xenografts alters the tumor redox status to potentiate radiotherapy.
- (2020) Shun Kishimoto et al. ANTIOXIDANTS & REDOX SIGNALING
- Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
- (2019) Roger M. Phillips et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000
- (2019) Xinjian Mao et al. CANCER BIOLOGY & THERAPY
- Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
- (2019) Linda Spiegelberg et al. RADIOTHERAPY AND ONCOLOGY
- Tandem activated photodynamic and chemotherapy: Using pH-Sensitive nanosystems to realize different tumour distributions of photosensitizer/prodrug for amplified combination therapy
- (2019) Yu Ji et al. BIOMATERIALS
- P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets
- (2018) V Domenyuk et al. ANNALS OF ONCOLOGY
- Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies
- (2018) Yoichi Takakusagi et al. ANTIOXIDANTS & REDOX SIGNALING
- Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: Multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring
- (2018) Shihong Shen et al. BIOMATERIALS
- Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy
- (2018) Rui Zhang et al. BIOMATERIALS
- Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
- (2018) Andrew Brenner et al. NEURO-ONCOLOGY
- Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
- (2018) Joel P. Joseph et al. ORAL ONCOLOGY
- Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models
- (2018) Sushil Kumar et al. Translational Oncology
- A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia
- (2018) Xin Luan et al. Advanced Science
- Chemotherapeutic Drug Based Metal-Organic Particles for Microvesicle-Mediated Deep Penetration and Programmable pH/NIR/Hypoxia Activated Cancer Photochemotherapy
- (2018) Da Zhang et al. Advanced Science
- 18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
- (2018) Milan Grkovski et al. EJNMMI Research
- Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.
- (2018) Jack P. Higgins et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- Hybrid Nanomedicine Fabricated from Photosensitizer-Terminated Metal-Organic Framework Nanoparticles for Photodynamic Therapy and Hypoxia-Activated Cascade Chemotherapy
- (2018) Zhimei He et al. Small
- An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
- (2018) Xinjian Mao et al. PLoS Computational Biology
- Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer
- (2017) R. M. Phillips et al. Expert Opinion on Drug Metabolism & Toxicology
- The efficacy of Apaziquone in the treatment of bladder cancer
- (2017) Francisco Caramés Masana et al. EXPERT OPINION ON PHARMACOTHERAPY
- Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer
- (2017) Robert F. Anderson et al. FREE RADICAL BIOLOGY AND MEDICINE
- Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage
- (2017) Mans Broekgaarden et al. Journal of Biomedical Nanotechnology
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
- (2017) William D Tap et al. LANCET ONCOLOGY
- Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing
- (2017) Aurélien Voissiere et al. PLoS One
- A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model
- (2017) Carla Hajj et al. Translational Oncology
- The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
- (2017) Katarzyna J. Nytko et al. Oncotarget
- Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
- (2017) Vasilios Liapis et al. Cancer Medicine
- Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy
- (2016) Liangzhu Feng et al. ACS Nano
- Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
- (2016) Talha Badar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models
- (2016) Jessica D. Sun et al. CANCER BIOLOGY & THERAPY
- Hypoxia: A Double-Edged Sword in Cancer Therapy
- (2016) Hamed Manoochehri Khoshinani et al. CANCER INVESTIGATION
- Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
- (2016) Rafael Duran et al. CLINICAL CANCER RESEARCH
- The impact of hypoxia and its modification of the outcome of radiotherapy
- (2016) Michael R. Horsman et al. JOURNAL OF RADIATION RESEARCH
- PD11-07 INTEGRATED RESULTS OF TWO MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, PHASE 3 TRIALS (SPI-611/612) OF SINGLE-DOSE INTRAVESICAL APAZIQUONE IMMEDIATELY FOLLOWING RESECTION IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER
- (2016) Lawrence Karsh et al. JOURNAL OF UROLOGY
- MP13-07 IMPROVED EFFICACY OF ADJUVANT, SINGLE DOSE INTRAVESICAL APAZIQUONE BY TIMING POST-RESECTION IN TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES IN NON-MUSCLE INVASIVE BLADDER CANCER
- (2016) Fred Witjes et al. JOURNAL OF UROLOGY
- Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase
- (2016) MANAL MEHIBEL et al. ONCOLOGY REPORTS
- Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice
- (2016) Wei-Hsiang Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors
- (2016) Stephanie L. Ham et al. Advanced Healthcare Materials
- Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
- (2016) Danika Lindsay et al. PLoS Computational Biology
- Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models
- (2016) Vasilios Liapis et al. Cancer Medicine
- AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia
- (2015) D. Moradi Manesh et al. BLOOD
- Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
- (2015) Fanying Meng et al. BMC CANCER
- Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
- (2015) Maria R Abbattista et al. CANCER BIOLOGY & THERAPY
- Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma
- (2015) Vasilios Liapis et al. CANCER LETTERS
- Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
- (2015) F. W. Hunter et al. CANCER RESEARCH
- Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases
- (2015) Roben G. Gieling et al. CLINICAL & EXPERIMENTAL METASTASIS
- Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
- (2015) L. Zhang et al. CLINICAL CANCER RESEARCH
- Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
- (2015) J. Benito et al. CLINICAL CANCER RESEARCH
- Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation--An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
- (2015) J. K. Saggar et al. CLINICAL CANCER RESEARCH
- 18F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer
- (2015) Ya-Li Cui et al. Future Oncology
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
- (2015) M. Konopleva et al. HAEMATOLOGICA
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
- (2015) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy
- (2015) Gunjan Srivastava et al. PLoS One
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
- (2015) M. Konopleva et al. HAEMATOLOGICA
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
- (2014) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
- (2013) S. Portwood et al. CLINICAL CANCER RESEARCH
- 18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model
- (2013) S. K. Chitneni et al. JOURNAL OF NUCLEAR MEDICINE
- The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
- (2013) Annika Foehrenbacher et al. Frontiers in Oncology
- PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
- (2012) Mark J McKeage et al. BMC CANCER
- EO9 (Apaziquone): from the clinic to the laboratory and back again
- (2012) Roger M Phillips et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation
- (2012) K. M. Govaert et al. BRITISH JOURNAL OF SURGERY
- Is there a role for tirapazamine in the treatment of cervical cancer?
- (2012) Prafull Ghatage et al. Expert Opinion on Drug Metabolism & Toxicology
- Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: Informed scheduling of the bioreductive drug AQ4N improves treatment response
- (2012) Louise Ming et al. INTERNATIONAL JOURNAL OF CANCER
- Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia inγ-ray irradiation in terms of local tumour response and lung metastatic potential
- (2012) Shin-Ichiro Masunaga et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs
- (2011) Francis W. Hunter et al. BIOCHEMICAL PHARMACOLOGY
- A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
- (2011) Mark J McKeage et al. BMC CANCER
- PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
- (2011) Ghassan K. Abou-Alfa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
- (2011) J. D. Sun et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
- (2011) J. Wang et al. CLINICAL CANCER RESEARCH
- Cytochrome P450 2S1 is Reduced by NADPH-Cytochrome P450 Reductase
- (2011) Y. Xiao et al. DRUG METABOLISM AND DISPOSITION
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
- (2011) Juliana Benito et al. PLoS One
- CYP2S1 is negatively regulated by corticosteroids in human cell lines
- (2011) Ilona G. Bebenek et al. TOXICOLOGY LETTERS
- Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
- (2010) J. Hu et al. BLOOD
- Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice
- (2010) Yongchuan Gu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
- (2010) C. P. Guise et al. CANCER RESEARCH
- Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
- (2010) K. O. Hicks et al. CLINICAL CANCER RESEARCH
- Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics
- (2010) E. E. Graves et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer
- (2010) Danny Rischin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- High 18F-FDG Uptake in Microscopic Peritoneal Tumors Requires Physiologic Hypoxia
- (2010) X. F. Li et al. JOURNAL OF NUCLEAR MEDICINE
- Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1
- (2010) C. R. Nishida et al. MOLECULAR PHARMACOLOGY
- A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
- (2009) Michael B. Jameson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone
- (2009) O. Tredan et al. CANCER RESEARCH
- DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity
- (2009) R. S. Singleton et al. CANCER RESEARCH
- Pharmacologically Increased Tumor Hypoxia Can Be Measured by 18F-Fluoroazomycin Arabinoside Positron Emission Tomography and Enhances Tumor Response to Hypoxic Cytotoxin PR-104
- (2009) R. A. Cairns et al. CLINICAL CANCER RESEARCH
- Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
- (2009) J. Doloff et al. CURRENT CANCER DRUG TARGETS
- Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography
- (2009) Xiao-Feng Li et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation
- (2009) Bo Hong et al. INVESTIGATIONAL NEW DRUGS
- Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
- (2009) Y. Gu et al. MOLECULAR CANCER THERAPEUTICS
- In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
- (2009) K. J. Williams et al. MOLECULAR CANCER THERAPEUTICS
- Hypoxia in microscopic tumors
- (2008) Xiao-Feng Li et al. CANCER LETTERS
- Evaluation of the Antiangiogenic Potential of AQ4N
- (2008) M. O'Rourke et al. CLINICAL CANCER RESEARCH
- Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
- (2008) M. R. Albertella et al. CLINICAL CANCER RESEARCH
- A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
- (2008) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started